Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the upcoming
presentation of six scientific posters at the 24th European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
taking place May 10-13, 2014 in Barcelona, Spain.
"We are excited to be presenting data on multiple antibiotic candidates
at ECCMID this year," said Guy
Macdonald, President and CEO of Tetraphase. "Notably, the
presentations cover new safety data on our Phase 3 antibiotic candidate
eravacycline; preclinical studies demonstrating in vivo efficacy
of eravacycline and our preclinical candidate TP-271 against certain
biothreat pathogens; and additional preclinical data from the newest
drug candidates discovered through our in-house antibiotic chemistry
platform. We are particularly pleased with the activity of these early
stage compounds against some of the most difficult-to-treat
Gram-negative pathogens, including species of Carbapenem-resistant
Enterobacteriaceae (CRE), bacteria specifically identified by the
CDC and the World Health Organization as urgent threats to public
Poster #P0301 entitled, "Eravacycline
Does Not Prolong Corrected QT Intervals in a Thorough QT Study Conducted
in Healthy Subjects," will be presented during the session on
New Therapeutic Alternatives from 3:30 PM to 4:30 PM CEST on Saturday,
Poster #P0109, entitled "Eravacycline
Protects in a Bacillus anthracis-Infected New Zealand White
Rabbit Treatment Model," will be presented during the session on
Animal Models from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
Poster #P1228, entitled "Multi-Locus
Sequence Typing of Escherchia coli Isolates from a Phase 2
Complicated Intra-Abdominal Trial for Eravacycline," will be
presented during the session on Global Epidemiology and Molecular Typing
from 1:30 PM to 2:30 PM CEST on Monday, May 12th.
Eravacycline is a fully synthetic tetracycline derivative being
developed by Tetraphase as an intravenous and oral antibiotic for the
treatment of serious, resistant Gram-negative infections.
Poster #P0111, entitled "TP-271,
a Novel Fluorocycline, is Efficacious in a Treatment Model of
Aerosolized Francisella tularensis Infection in BALB/c Mice,"
will be presented during the session on Animal Models from 3:30 PM to
4:30 PM CEST on Saturday, May 10th.
TP-271, a novel tetracycline antibiotic currently in preclinical
development, is being developed to combat respiratory disease caused by
bacterial biothreats and antibiotic-resistant pathogens.
Generation Gram-negative Program Presentations
Poster #P0299, entitled "In
Vitro Potency of Novel, Fully Synthetic Tetracyclines against MDR
Gram-negative Pathogens Including Carbapenem-resistant Enterobacteriaceae,"
will be presented during the session on New Therapeutic Alternatives
from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
Poster #P0300, entitled "In
Vivo Efficacy of Novel, Fully Synthetic Tetracyclines in a Murine
Lung Infection Model Challenged with KPC-producing Klebsiella
pneumoniae," will be presented during the session on New Therapeutic
Alternatives from 3:30 PM to 4:30 PM CEST on Saturday, May 10th.
Tetraphase's 2nd-Generation Gram-negative Program is focused
on the discovery of tetracycline-derived compounds active against the
most urgent multidrug-resistant Gram-negative bacterial health threats
identified by the CDC in its September
Notes on Studies
The studies supporting posters P0109 and P0301 were funded in whole or
in part with Federal Funds from the Biomedical Advanced Research and
Development Authority (BARDA), Office of the Assistant Secretary for
Preparedness and Response, Office of the Secretary, Department of Health
and Human Services, under Contract No HHSO100201200002C.
The studies supporting poster P0111 were funded by the National
Institute of Allergy and Infectious Diseases (NIAID) Participation Grant
#: 1R01AI093484-01 and NIAID Contract #: HHSN272201100028C.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for serious
and life-threatening multidrug-resistant (MDR) bacterial infections,
including those caused by many of the MDR Gram-negative bacteria
highlighted as urgent public health threats by the Centers for Disease
Control and Prevention (CDC). Tetraphase's lead product candidate,
eravacycline, is being developed as a broad-spectrum intravenous and
oral antibiotic in the IGNITE program (Investigating Gram-negative
Infections Treated with Eravacycline). Under this
program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the
indication of complicated intra-abdominal infections (cIAI) and IGNITE 2
for complicated urinary tract infections (cUTI). Tetraphase has created
more than 3,000 novel tetracycline analogs using its technology
platform; in addition to eravacycline, Tetraphase has generated multiple
preclinical antibiotic candidates that are currently being evaluated for
clinical suitability. Please visit www.tphase.com
for more company information.
Any statements in this press release about our future expectations,
plans and prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, and other statements
containing the words "anticipates," "believes," "expects," "plans,"
"will" and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: whether results obtained in preclinical studies and
early clinical trials will be indicative of results obtained in future
clinical trials; whether our drug candidates will advance through the
clinical trial process on a timely basis or at all; and other factors
discussed in the "Risk Factors" section of our most recent Annual Report
on Form 10-K, filed with the Securities and Exchange Commission on March
6, 2014. In addition, the forward-looking statements included in this
press release represent our views as of May 9, 2014. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
at some point in the future, we specifically disclaim any obligation to
[ Back To NFVZone's Homepage ]